Ask AI
Novel Therapeutic Targets for RR MM

CME

Next-Generation Approaches for Relapsed Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: July 17, 2025

Expiration: January 16, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following best describes differences between novel CELMoDs and approved IMiDs in regulating myeloma cell proliferation and modulating immune responses?

2.

In your current practice, how likely would you be to consider a treatment for multiple myeloma that was approved based on MRD-negative CR data?

3.

Which investigational CELMoD is currently being evaluated in phase III trials enrolling patients with multiple myeloma in the post-ASCT maintenance and relapsed/refractory settings?

4.

A patient with heavily pretreated MM is interested in a clinical trial of CELMoD therapy. Which of the following would you tell them is the grade 3/4 AE that has been most frequently observed in patients treated with iberdomide and mezigdomide in clinical trials?